First-in-class metabolic drugs with breakthrough biochemistry
Targeting NAMPT, a core regulator of human biology
All human cells require energy (e.g., sugar and fat) to function and survive, and the NAMPT enzyme controls how cells use energy. Well-regulated NAMPT activity is paramount to human health, with thousands of research articles connecting NAMPT dysregulation to more than 20 distinct diseases, spanning oncology, autoimmune and metabolic disorders. To treat these numerous diseases, many Pharma companies tried to make NAMPT-targeting drugs; however, they all caused significant on-target toxicity and none have advanced beyond Phase 2 clinical trials.
A new approach
Our clinical candidate, RPT1G, is a first-of-its-kind solution that categorically avoids the toxic effects that have plagued prior NAMPT drug candidates. This breakthrough stems from our proprietary drug screening platform, which led to novel drug chemistry and an unprecedented mechanism of action.
- More on Our Science
The technology and research program at Remedy Plan are both exciting and novel. They have a great opportunity to develop drugs that effectively block cancer recurrence and metastasis.
Founder of Onyx Pharmaceuticals, professor at the UCSF Helen Diller Cancer Center, Fellow of Royal Society, and member of the National Academies of Science
- Lead Optimization
- Phase I
- NAMPT - Oncology: RPT1G
- NAMPT - Autoimmune
- NAMPT - Obesity
- Target 2
I'm very impressed by the creative and novel approach being used by Remedy Plan to identify new drugs that render cancer cells harmless.
Professor at UC Berkeley, member of the National Academies of Science, and an NIH Merit Award recipient